Coumarin (1,2-benzopyrone) is a natural compound that has been used as a fragrance in the food and perfume industry and could have therapeutic usefulness in the treatment of lymphedema and different types of cancer. Several previous pharmacokinetic studies of coumarin have been performed in humans, which revealed extensive first-pass metabolism of the compound. 7-Hydroxycoumarin (7-HC) and its glucuronide (7-HC-G) are the main metabolites formed in humans, and via this route, 80 to 90% of the absorbed coumarin is excreted into urine, mainly as 7-HC-G. Active transport processes play a role in the urinary excretion of 7-HC-G; however, until now, the transporters involved remained to be elucidated. In this study, we investigated whether the efflux transporters multidrug resistance-associated proteins (MRP)1-4, breast cancer resistance protein, or P-glycoprotein play a role in 7-HC and 7-HC-G transport. For this purpose, we measured uptake of the metabolites into membrane vesicles overexpressing these transporters. Our results showed that 7-HC is not transported by any of the efflux transporters tested, whereas 7-HC-G was a substrate of MRP3 and MRP4. These results are in line with the pharmacokinetic profile of coumarin and suggest that MRP3 and MRP4 are the main transporters involved in the excretion of the coumarin metabolite 7-HC-G from liver and kidney.
Introduction
Coumarin (1,2-benzopyrone) is a natural compound that is found in many plants, e.g., the Tonka bean and cinnamon bark oil (Fig. 1A) . It has been used as a fragrance in perfume and food, and coumarin and its metabolites have also been shown to be effective as medicinal therapy, reducing lymphedema and having antitumor activity (Lake, 1999; Lacy and O'Kennedy, 2004) . However, in rodents, coumarin causes hepatotoxicity, which led to restricted usage of this compound in the food and fragrance industry and in medicinal therapy (Egan et al., 1990) .
Because coumarin is naturally present in food and is suggested to have a potential therapeutic value, many studies have been performed to obtain insight into its pharmacokinetic characteristics in humans. Sampling human plasma after oral administration of coumarin showed that, although almost completely absorbed, only 2 to 6% reaches the systemic circulation (Ritschel et al., 1979) . This is attributed to extensive first-pass metabolism of coumarin to 7-hydroxycoumarin (7-HC) by CYP2A6, and, subsequently, to its glucuronide (7-HC-G) and sulfate conjugates by uridine 5Ј-diphosphoglucuronosyltransferases (UGTs) and sulfotransferases, respectively (Ritschel et al., 1979; Lake, 1999; Ford et al., 2001; Wang et al., 2006) . Because coumarin 7-hydroxylation is mainly mediated via CYP2A6, it has been used as a model substrate for CYP2A6 activity in humans (Lake, 1999) . In addition, 7-HC is used as a model substrate for the investigation of glucuronidation activity of liver and intestinal models because many UGTs have the capability to glucuronidate this compound (De Kanter et al., 2002; Brown et al., 2003; van de Kerkhof et al., 2006) (Fig. 1). 7-HC-G represents the main metabolite in plasma, indicating that it is formed in intestine or liver, and at a low dose of coumarin, approximately 80 to 90% of the absorbed dose of coumarin is excreted in urine, mainly as 7-HC-G, whereas Ͻ1% is excreted via the feces (Shilling et al., 1969; Ritschel et al., 1977; Ford et al., 2001) . At higher doses of coumarin, the metabolism seems to become saturated, which is reflected in a lower percentage of 7-HC and 7-HC-G excretion in urine (55-63%) (Egan et al., 1990; Asimus et al., 2008) .
The clearance of 7-HC-G exceeds the glomerular filtration rate; therefore, it is considered to be actively secreted into the urine by the tubular segments in the kidney (Ritschel et al., 1977) . Efflux transporters belonging to the ATP-binding cassette family, such as multidrug-resistance associated proteins (MRPs), breast cancer resistance protein (BCRP), and P-glycoprotein (P-gp) are known to play a role in the active tubular secretion of compounds from the kidney (Schinkel and Jonker, 2003; El-Sheikh et al., 2008) . Until now, the ATPbinding cassette transporters involved in the disposition of the 7-hydroxycoumarin metabolites have not been identified. To study the role of the most important drug efflux transporters in the handling of 7-HC and 7-HC-G, we determined the ATP-dependent uptake of these metabolites in membrane vesicles overexpressing MRP1-4, P-gp, and BCRP.
Materials and Methods
Materials. 7-HC, 7-HC-G, ATP (from bacterial source), adenosine 5Ј-monophosphate monohydrate (AMP) (from yeast), estrone sulfate (E 1 S), estradiol 17-␤-D-glucuronide (E 2 17␤G), DL-dithiothreitol, and GSH were purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). Multiscreen HTS filter plates and Vacuum Manifold filtration device were from Millipore (Etten-Leur, the Netherlands). [6, Production of Membrane Vesicles Overexpressing the Efflux Transporters. Human embryonic kidney 293 cells were transduced with baculovirus encoding MRP1-4, BCRP, P-gp, or enhanced yellow fluorescent protein (negative control protein), and 3 days after transduction, cells were harvested and membrane vesicles were made following a previously described protocol, with the exception that during vesicle isolation, the homogenized cells were spun down at 4000g instead of 1000g for 20 min (Wittgen et al., 2011) . Protein expression and the functionality of each batch of membrane vesicles were confirmed via immunoblot (data not shown) and in a radioactive vesicular transport assay using [ 3 H]E 2 17␤G for MRP1-4 and [6,7-3 H(N)]E 1 S for BCRP, according to the protocols described previously and using concentrations and time points as indicated in the legend of Fig. 2 (Mutsaers et al., 2011; Wittgen et al., 2011) . Functionality of P-gp vesicles was tested following the protocol of the vesicular transport assay described below, with the exception that 0.015 Ci [ 3 H]NMQ in a total concentration of 100 nM NMQ was used instead of 7-HC or 7-HC-G. Furthermore, samples were separated using a prewashed Multiscreen HTS HV (0.45 M) glass fiber 96-well filter plate. NMQ was extracted from the filters using 2 ml of scintillation fluid and by subsequent liquid scintillation counting of [ 3 H]NMQ associated with the filters, in the uptake of total NMQ into the membrane vesicles was calculated.
Vesicular Transport Assay with 7-HC and 7-HC-G. Uptake of 7-HC and 7-HC-G into membrane vesicles was performed using a rapid filtration technique. The reaction mixture (30 l) consisted of TS buffer (10 mM Tris-HEPES, and 250 mM sucrose, pH 7.4), 4 mM ATP, 10 mM MgCl 2 , 7-HC or 7-HC-G, and 7.5 g of membrane vesicles. Concentrations of 7-HC and 7-HC-G and time points taken for measurements are indicated in the figure legends. To test the effect of GSH on transport of 7-HC via MRP1-4 and transport of 7-HC-G via MRP1 and MRP2, the experiment was also performed in presence of 3 mM GSH and 10 mM DL-dithiothreitol to prevent oxidation of GSH (Leslie et al., 2001; Maeno et al., 2009 ). The reaction was started when the mixture was incubated at 37°C and stopped by placing the samples on ice and adding 150 l of ice-cold TS buffer. A Multiscreen HTS HV (0.45 M) polyvinylidene difluoride 96-well filter plate was prewashed with TS buffer and diluted samples were filtered through this filter plate using a Multiscreen HTS -Vacuum Manifold filtration device. The filters were washed twice with TS-buffer and were then separated from the plate. Compounds were extracted from filters by incubation with 20% acetonitrile for 1 h at room temperature and vortexing thoroughly, and extracted samples were analyzed by high-performance liquid chromatography (HPLC). In control experiments, ATP was substituted with AMP. Net ATP-dependent transport was calculated by subtracting values measured in the presence of AMP from those measured in the presence of ATP.
HPLC Analysis of 7-HC and 7-HC-G. The concentration of 7-HC and 7-HC-G in the samples was analyzed using reversed-phase HPLC and fluorescence detection with excitation and emission wavelengths set at 316 and 382 nm, respectively. The HPLC consisted of a P2000 pump, an AS3000 autosampler, and a FL3000 fluorescence detector (Thermo Fisher Scientific, Waltham, MA). Compounds were separated on a Grace-Smart RP-18 column (150 ϫ 4.6 mm, 5 m; Grace Division Discovery Sciences, Deerfield, IL). The temperature of the column was set at 40°C, and the injection volume was 50 l. The mobile phase composition was 5% methanol and 0.2% acetic acid in water for solvent A and 50% acetonitrile with 0.1% tetrahydrofuran for solvent B. Separation was achieved using a linear gradient from 20% B to 50% B in 8 min, with a flow rate of 1 ml/min. Standard curve calibrations were performed on a concentration range of 7-HC (0.3-5 M) and 7-HC-G (10 -500 nM). Limit of quantification was 10 nM for 7-HC-G and 20 nM for 7-HC.
Data Analysis. All data were expressed as mean Ϯ S.E.M. Curve fitting of the concentration-dependent transport data were performed using MichaelisMenten kinetic analysis in Prism software, version 5.02 (GraphPad Software Inc., San Diego, CA). 
Results

Identification of Transporters Involved in 7-HC and 7-HC-G
Transport. Transport of 7-HC and 7-HC-G via MRP1-4, BCRP, or P-gp was investigated using membrane vesicles overexpressing these transporters. After incubation with 400 M 7-HC, all values for 7-HC in the membrane vesicles were below the detection limit, and there was no ATP-dependent increase of 7-HC (data not shown). The addition of 3 mM GSH, a well known cofactor for MRP-mediated transport, did not increase 7-HC uptake into MRP1-4 vesicles (data not shown). Transport of control substrates via MRP1-4, BCRP, and P-gp illustrated functionality of all transporters (Fig. 2) . Therefore, the lack of ATP-dependent increase of 7-HC under the given circumstances suggests that 7-HC is not a substrate for these transporters. Values for 7-HC-G in the presence of AMP were also below the detection limit for the glucuronide metabolite 7-HC-G after incubation with 400 M 7-HC-G. However, there was a clear ATP-dependent increase of 7-HC-G into MRP3-and MRP4-overexpressing vesicles, which was highest for MRP4 (Fig. 3) . No ATP-dependent uptake of 7-HC-G was observed in membrane vesicles overexpressing MRP1, MRP2, BCRP, or P-gp under the conditions used, and the addition of 3 mM GSH did not increase transport via MRP1 and MRP2. This indicates that 7-HC-G is a substrate of MRP3 and MRP4, and not that of the other transporters.
Kinetic Characteristics of 7-HC-G Transport via MRP3 and MRP4. Transport of 7-HC-G over time was linear up to 20 min for both MRP3 and MRP4 (Fig. 4A) . Transport of different concentrations of 7-HC-G via MRP3 and MRP4 after 10 min showed normal Michaelis-Menten kinetics (Fig. 4B) . K m values for MRP3 and MRP4 were 187 Ϯ 22 and 63 Ϯ 11 M, respectively. V max values for MRP3 and MRP4 were 460 Ϯ 20 and 920 Ϯ 50 pmol mg Ϫ1 min Ϫ1 , respectively.
Discussion
In this study, we found that 7-HC-G is transported by the efflux transporters MRP3 and MRP4, whereas 7-HC is not transported by any of the efflux transporters studied. These results are in line with the distribution of these transporters in the human body and the pharmacokinetic profile of coumarin and its metabolites.
The fact that 7-HC is not transported via efflux transporters is in accordance with a previous study in which no transport of 7-HC via P-gp was found (Finn et al., 2004) . Furthermore, perfusion studies in intestine from guinea pigs indicated that 7-HC is absorbed via passive transport processes in the intestine (Kaul and Ritschel, 1981) .
The results from our transport studies with 7-HC-G point toward an important role for MRP3 in the efflux of this compound from the liver and for MRP4 in the urinary excretion of 7-HC-G from the body. Although plasma concentrations in humans after clinical or foodderived doses of coumarin are low (1-4 M) compared with the K m of 7-HC-G for MRP3 (187 M) and MRP4 (63 M), the rate of efflux will mainly depend on the intracellular concentration of 7-HC-G, which may very well be higher than the plasma 7-HC-G concentration (Ritschel et al., 1979; Ritschel and Hoffmann, 1981; Ford et al., 2001; Abraham et al., 2011) . MRP3 is mainly expressed at the basolateral surface of cells in the small intestine, colon, liver, and kidney (thick ascending loop and distal convoluted tubule cells) (Scheffer et al., 2002) , and MRP4 has a dual membrane localization, which is basolateral, but minimal in hepatocytes, apical in kidney proximal tubule FIG. 3 . ATP-dependent transport of 7-HC-G by the efflux transporters MRP1-4, BCRP, and P-gp into membrane vesicles overexpressing these transporters or control protein (ctrl). Transport was measured after 10 min of uptake in the presence of 400 M 7-HC-G at 37°C, and uptake per milligram membrane vesicles per minute is plotted in the graph. Mean Ϯ S.E.M. of three independent experiments is shown .   FIG. 4 . Time-and concentration-dependent uptake for 7-HC-G uptake into control (F), MRP3 (छ), and MRP4 (OE) overexpressing membrane vesicles. A, uptake was measured in the presence of 400 M 7-HC-G at time points indicated on the x-axis, and uptake per milligram membrane vesicles is plotted in the graph. B, uptake was measured after 10 min at concentrations of 7-HC-G indicated on the x-axis, and uptake per milligram membrane vesicles per minute is plotted in the graph. A Michaelis-Menten curve was fitted through the data points. Mean Ϯ S.E.M. of three independent experiments is shown for both graphs.
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at ASPET Journals on November 6, 2017 dmd.aspetjournals.org cells, and still unresolved in intestinal epithelium . After oral administration, coumarin enters the enterocytes, most probably via a passive drug-transfer process (Kaul and Ritschel, 1981) . Because the intestine seems to lack CYP2A6, the 7-hydroxylating enzyme of coumarin, oxidative metabolism, and subsequent glucuronidation of coumarin in enterocytes are limited (Zhang et al., 1999) . After passage across the intestinal wall into the blood, coumarin will enter the liver where 7-hydroxylation to 7-HC and glucuronidation to 7-HC-G will take place. Our results suggest that the glucuronide metabolite 7-HC-G is subsequently transported via the basolateral transporter MRP3 into the circulation and not to the bile because it is not transported via the canalicular transporters MRP2, BCRP, or P-gp. After entering the general circulation, 7-HC-G will be taken up into the kidney proximal tubular cells, most probably via an organic anion transporter that remains to be identified (e.g., OAT1 or OAT3), and will be excreted via MRP4 at the apical side of these cells, which completes the urinary excretion of 7-HC-G.
Transporter-mediated efflux of glucuronide conjugates is an important step in the overall glucuronidation activity of a cell or tissue (Jeong et al., 2005) . This implies that not only UGT activity but also MRP3 or MRP4 transport capacity of cells can influence the rate of glucuronidation, which should be kept in mind when using 7-HC as a model compound for determining UGT activity. Furthermore, deleterious polymorphisms of MRP3 and MRP4 might alter the metabolic route for coumarin from glucuronidation to sulfation, or possibly even toward more toxic pathways (Lake, 1999; Farinola and Piller, 2007; Abla et al., 2008; Kobayashi et al., 2008) . In summary, this study showed that MRP3 and MRP4 are the efflux transporters involved in disposition and excretion of the main metabolite of coumarin, 7-HC-G, in humans.
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